Latest stories on QNTM
Quantum BioPharma (NASDAQ: QNTM) Draws ‘Men’s Fitness’ Spotlight as Unbuzzd Trial Shows Early Promise
Business Insider58 · neutralproduct/pr
Quantum to Announce Fiscal Second Quarter 2027 Financial Results on November 9, 2026
StockTitan50 · neutralgeneral
Quantum BioPharma (NASDAQ: QNTM) Featured in Men’s Fitness Article Examining Unbuzzd Clinical Trial Results
Business Insider56 · neutralproduct/pr
Quantum BioPharma’s Phase 2 Shows Where Biotech Value Actually Gets Built
MarketBeat58 · neutralproduct/pr
Quantum expects to ‘meet or exceed’ previously issued guidance
The Fly58 · neutralearnings
Quantum BioPharma Wins Consolidation of Market-Manipulation Lawsuits Against CIBC and RBC
TipRanks58 · neutralgeneral
Quantum BioPharma Ltd. (NASDAQ: QNTM) Enters Study Start-Up Agreement for Lucid-MS Phase 2 Trial
Business Insider63 · neutralproduct/pr
Quantum BioPharma (NASDAQ: QNTM) Enters Study Start-Up Agreement for Lucid-MS Phase 2 Trial
Business Insider63 · neutralproduct/pr
Quantum BioPharma signs contract with Thermo Fisher for sclerosis trial
The Fly63 · neutralproduct/pr
Quantum BioPharma Signs Contract with Thermo Fisher Scientific’s Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis
Business Insider67 · bullishproduct/pr
IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.
Business Insider50 · neutralgeneral
Quantum BioPharma (NASDAQ: QNTM) Receives FDA Green Light to Move Lucid-MS into Phase 2 Testing
Business Insider73 · bullishproduct/pr
Quantum BioPharma Licensee Unbuzzd Taps New CEO Ahead of Planned Listing
TipRanks58 · neutralgeneral
Quantum BioPharma licensee Unbuzzed Wellness appoints Zapolin as CEO
The Fly55 · neutralgeneral
Quantum BioPharma (NASDAQ: QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments
Business Insider63 · neutralproduct/pr
Quantum BioPharma reports Q4 results
Seeking Alpha56 · neutralearnings
Quantum BioPharma Highlights Year of Financing Moves, Debt Settlement and Governance Changes
TipRanks55 · neutralgeneral
Quantum BioPharma (NASDAQ: QNTM) Announces that Rodman & Renshaw Initiates Coverage with Buy Rating, $8 Price Target
Business Insider61 · neutralanalyst
Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target
GlobeNewswire61 · neutralanalyst